Ainos Inc

Ainos Inc(AIMD)股票分析

$0.960

0.000 (0.00%)收盘时

Loading chart…
最高
1.030
开盘
0.930
成交量加权均价
0.95
成交量
68.99K
市值
5.50M
最低
0.870
成交额
65.78K
企业价值/息税折旧摊销前利润(TTM)
0.00

Ainos, Inc. is a dual-platform AI and biotech company advancing SmellTech and immune therapeutics. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. It is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions.

AI 分析 of Ainos Inc (AIMD)

卖出

Ainos Inc is not a good buy right now due to its poor financial performance and negative momentum indicators. The current price is $1.21, and the RSI is at 27.229, indicating oversold conditions but also suggesting continued weakness. Additionally, the forward P/E ratio is 13.9082, which is high given the company's declining revenues and increasing losses, with a 1-year change of -69.29%.

估值指标

Ainos Inc(AIMD)当前预期市盈率为 13.91,5 年平均预期市盈率为 2.25。

预期市盈率

严重高估
5 年均值 P/E
2.25
当前P/E
13.91
高估
7.35
低估
-2.84

预期 EV/EBITDA

严重低估
5 年均值 EV/EBITDA
0.00
当前EV/EBITDA
0.00
高估
0.00
低估
0.00

预期市销率

严重低估
5 年均值 P/S
0.00
当前P/S
0.00
高估
0.00
低估
0.00

Alphio AI 对 AIMD 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%AIMD

$3.22

情景价格

基

基准

基准 · 50%AIMD

$2.84

情景价格

悲

悲观

悲观 · 25%AIMD

$2.25

情景价格

事件时间线

2026-09-30 (ET)

10:00:00

Ainos Completes VELDONA Data Delivery, Triggers $600,000 Initial Payment

2026-09-29 (ET)

08:30:00

Ainos Completes Delivery of 1,400 AI Nose Systems to ASE

2026-09-28 (ET)

09:00:00

Ainos VELDONA License Agreement Initial Fee of $600,000

2026-09-24 (ET)

09:00:00

Ainos Enters VELDONA License Agreement with BioPhoenix, Potential Value of $10M

2026-09-14 (ET)

08:30:00

Ainos Launches Second-Gen AI Nose Platform, Secures Initial Orders

资讯

AIMD 常见问题 —— 由 Alphio AI 解答

Ainos, Inc. is a dual-platform AI and biotech company advancing SmellTech and immune therapeutics. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. It is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ainos Inc is not a good buy right now due to its poor financial performance and negative momentum indicators. The current price is $1.21, and the RSI is at 27.229, indicating oversold conditions but also suggesting continued weakness. Additionally, the forward P/E ratio is 13.9082, which is high given the company's declining revenues and increasing losses, with a 1-year change of -69.29%.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易